Quantcast

Latest Tacrolimus Stories

2014-08-20 16:24:51

HORSHOLM, Denmark, Aug. 20, 2014 /PRNewswire/ -- Highlights: -- On 28 July the European Commission granted marketing authorization for Envarsus® for the prevention of organ rejection in adult kidney and liver transplant patients in the European Union (EU). -- Following the European marketing authorization Veloxis will receive a milestone payment of USD 15 million from our European partner Chiesi in the third quarter 2014 which is in line with...

2014-07-28 13:28:02

University of Oxford Oxford University scientists have shown that a powerful drug given at the time of a kidney transplant operation not only halves the early risk of rejection, but that it also allows a less toxic regimen of anti-rejection drugs to be used after the operation. The key results are reported in The Lancet and presented at the World Transplant Congress in San Francisco today. They will help doctors faced with a difficult transplant conundrum: the powerful combinations of...

2014-06-30 08:29:40

- Result seen across stable and de novo kidney transplant patients - HORSHOLM, Denmark, June 30, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that once-daily Envarsus(®) XR (tacrolimus extended-release tablets), an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients, demonstrated a lower treatment failure rate in African-Americans compared with twice-daily tacrolimus (Prograf(®)). These study...

2014-06-03 16:25:04

HORSHOLM, Denmark, June 3, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the hiring of senior level management in preparation for potential U.S. commercialization of Envarsus(®) XR (tacrolimus extended-release tablets) an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients. Key points: -- Envarsus( )XR is an extended release formulation of tacrolimus being designed for once-daily...

2014-05-22 04:21:28

HORSHOLM, Denmark, May 22, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a marketing authorization for Envarsus® for the prevention of organ rejection in adult transplant patients in the European Union (EU). The positive opinion is for both kidney and liver transplant recipients and includes both the...

2014-04-28 12:31:12

- Study published online in Liver Transplantation - HORSHOLM, Denmark, April 28, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the publication of a Phase II study demonstrating conversion from twice-daily tacrolimus to once-daily Envarsus(®) in stable liver transplant patients in Liver Transplantation. Key points: -- Envarsus(®) is an extended release formulation of tacrolimus designed for once-daily dosing, flatter pharmacokinetics and greater...

2014-04-16 16:30:36

LONDON, April 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_atopic_dermatitis_global_drug_forecast_market_analysis_2022.htmlPharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2022 SummaryAlthough the past decade has seen the atopic dermatitis market remain relatively unchanged...

2014-04-16 16:26:34

LONDON, April 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:PharmaPoint: Atopic Dermatitis - US Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_atopic_dermatitis_us_drug_forecast_market_analysis_2022.htmlPharmaPoint: Atopic Dermatitis - US Drug Forecast and Market Analysis to 2022SummaryAlthough the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated,...

2014-03-28 12:21:53

DUBLIN, Mar. 28, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/lwpmln/investigation ) has announced the addition of the "Investigation Report on China Tacrolimus Market, 2009-2018" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Tacrolimus, also named as ""FK506"" and ""FR-900506"", was developed by Fujisawa Pharmaceutical Co., Ltd. (later became Astellas Pharma by merging with Yamanouchi Pharmaceutical Co.,...

2014-03-15 08:21:40

In the news release, U.S. FDA Accepts Veloxis' New Drug Application for Envarsus® for the Prevention of Organ Rejection in Kidney Transplant Patients, issued 13-Mar-2014 by Veloxis Pharmaceuticals, we are advised that the first bullet should read "FDA has set a target review date under the Prescription Drug User Fee Act (PDUFA) of October 30, 2014" rather than "October 3, 2014" as originally issued inadvertently. The complete, corrected release follows: U.S. FDA Accepts Veloxis' New Drug...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'